Abstract
Vitamin D3 upregulated protein 1 (VDUP1) is a 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) upregulated protein, and it is induced by various stresses. In human tumor tissues, VDUP1 expression was downregulated. Upon stimulation by growth-inhibitory signals such as TGF-β1 and 1,25(OH)2D3, its expression was rapidly upregulated as the cell growth was retarded. The transfection of VDUP1 in tumor cells reduced cell growth. The VDUP1 expression was also increased when the cell-cycle progression was arrested. Transfection of VDUP1 induced cell-cycle arrest at the G0/G1 phase, indicating that VDUP1 possesses a tumor-suppressive activity. In addition, it was found that VDUP1 interacted with promyelocytic leukemia zinc-finger, Fanconi anemia zinc-finger, and histone deacetylase 1, which are known to be transcriptional corepressors. VDUP1 itself suppressed IL-3 receptor and cyclin A2 promoter activity. Taken together, these results suggest that VDUP1 is a novel antitumor gene which forms a transcriptional repressor complex.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cellular senescence in ischemia/reperfusion injury
Cell Death Discovery Open Access 18 October 2022
-
Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage
Cell Death & Disease Open Access 12 April 2022
-
Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity
Nature Communications Open Access 08 December 2016
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout








References
Banerjee D, Lenz HJ, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P and Bertino JR . (1995). Cell Growth Differ., 6, 1405–1413.
Bocchia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, Albino AP and Scheinberg DA . (1997). Leuk. Res., 21, 439–447.
Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA and Richon VM . (2002). Proc. Natl. Acad. Sci. USA, 99, 11700–11705.
Chen KS and DeLuca HF . (1994). Biochim. Biophys. Acta, 1219, 26–32.
Corn PG and El-Deiry WS . (2002). BioEssays, 24, 83–90.
Costoya JA and Pandolfi PP . (2001). Curr. Opin. Hematol., 8, 212–217.
David G, Alland L, Hong SH, Wong CW, DePinho RA and Dejean A . (1998). Oncogene, 16, 2549–2556.
Hoatlin ME, Zhi Y, Ball H, Silvey K, Melnick A, Stone S, Arai S, Hawe N, Owen G, Zelent A and Licht JD . (1999). Blood, 94, 3737–3747.
Junn E, Han SH, Im JY, Yang Y, Cho EW, Urn HD, Kim DK, Lee KW, Han PL, Rhee SG and Choi I . (2000). J. Immunol., 164, 6287–6295.
Kirshenbaum LA . (2001). Circ. Res., 88, 978–980.
Kramer OH, Gottlicher M and Heinzel T . (2001). Trends Endocrinol. Metab., 12, 294–300.
Li JY, English MA, Ball HJ, Yeyati PL, Waxman S and Licht JD . (1997). J. Biol. Chem., 272, 22447–22455.
Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH and Evans RM . (1998). Nature, 391, 811–814.
Ludwig DL, Kotanides H, Le T, Chavkin D, Bohlen P and Witte L . (2001). Gene, 269, 103–112.
Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V, Prive GG and Licht JD . (2002). Mol. Cell. Biol., 22, 1804–1818.
Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW and Licht JD . (2000). Blood, 96, 3939–3947.
Muller C, Yang R, Park DJ, Serve H, Berdel WE and Koeffler HP . (2000). Blood, 96, 3894–3899.
Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y and Yodoi J . (1999). J. Biol. Chem., 274, 21645–21650.
Olsson I, Bergh G, Ehinger M and Gullberg U . (1996). Eur. J. Haematol., 57, 1–16.
Pear WS, Nolan GP, Scott ML and Baltimore D . (1993). Proc. Natl. Acad. Sci. USA, 90, 8392–8396.
Piazza F, Gurrieri C and Pandolfi PP . (2001). Oncogene, 20, 7216–7222.
Piek JM, van Diest PJ, Verheijen RH and Kenemans P . (2001). Histopathology, 38, 481–482.
Rego EM, He LZ, Warrell Jr RP, Wang ZG and Pandolfi PP . (2000). Proc. Natl. Acad. Sci. USA, 91, 10173–10178.
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D and Brown PO . (2000). Nat. Genet., 24, 227–235.
Sainty D, Liso V, Cantu-Rajnoldi A, Head D, Mozziconacci MJ, Arnoulet C, Benattar L, Fenu S, Mancini M, Duchayne E, Mahon FX, Gutierrez N, Birg F, Biondi A, Grimwade D, Lafage-Pochitaloff M, Hagemeijer A and Flandrin G . (2000). Blood, 96, 1287–1296.
Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A and Licht JD . (1998). Mol. Cell. Biol., 18, 5533–5545.
Sherr CJ . (2000). Cancer Res., 60, 3689–3695.
Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K and Asai S . (2002). Oncol. Rep., 9, 75–79.
Taplick J, Kurtev V, Kroboth K, Posch M, Lechner T and Seiser C . (2001). J. Mol. Biol., 308, 27–38.
Wang C, Fu M, Mani S, Wadler S, Senderowicz AM and Pestell RG . (2001). Front. Biosci., 6, D610–D629.
Wang X and Studzinski GP . (2001). J. Cell Biochem., 80, 471–482.
Wang Y, De Keulenaer GW and Lee RT . (2002). J. Biol. Chem., 277, 26496–26500.
Ward JO, McConnell MJ, Carlile GW, Pandolfi PP, Licht JD and Freedman LP . (2001). Blood, 98, 3290–3300.
Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC and Deng CX . (2001). Nat. Genet., 28, 266–271.
Yang X, Young LH and Voigt JM . (1998). Breast Cancer Res. Treat., 48, 33–44.
Yeyati PL, Shaknovich R, Boterashvili S, Li J, Ball HJ, Waxman S, Nason-Burchenal K, Dmitrovsky E, Zelent A and Licht JD . (1999). Oncogene, 18, 925–934.
Zheng L and Lee WH . (2001). Exp. Cell Res., 264, 2–18.
Acknowledgements
This work was partially supported by a Grant FG-3-1-04 of 21C Frontier Functional Human Genome Project from Ministry of Science and Technology of Korea and by a KRF-99-042-D00127 of Korea Research Foundation Grant.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Han, S., Jeon, J., Ju, H. et al. VDUP1 upregulated by TGF-β1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22, 4035–4046 (2003). https://doi.org/10.1038/sj.onc.1206610
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206610
Keywords
- VDUP1
- tumor
- TGF-β1
- cell cycle
- PLZF
This article is cited by
-
Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage
Cell Death & Disease (2022)
-
Cellular senescence in ischemia/reperfusion injury
Cell Death Discovery (2022)
-
UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP
Oncogene (2019)
-
Clinical Significance of the Thioredoxin System and Thioredoxin-Domain-Containing Protein Family in Hepatocellular Carcinoma
Digestive Diseases and Sciences (2019)
-
Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication
Molecular Neurobiology (2018)